Alimera Sciences (NASDAQ:ALIM) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research note released on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on ALIM. Maxim Group reiterated a hold rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. HC Wainwright downgraded Alimera Sciences from a buy rating to a neutral rating and set a $6.00 target price for the company. in a research note on Tuesday, June 25th. Finally, Alliance Global Partners reiterated a neutral rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.

Alimera Sciences Price Performance

NASDAQ ALIM opened at $5.54 on Monday. The company has a quick ratio of 2.62, a current ratio of 2.79 and a debt-to-equity ratio of 1.80. The company has a market cap of $290.24 million, a PE ratio of -3.53 and a beta of 1.25. Alimera Sciences has a 52 week low of $2.61 and a 52 week high of $5.65. The firm’s 50-day simple moving average is $5.55 and its two-hundred day simple moving average is $4.51.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. The business had revenue of $27.00 million for the quarter, compared to analysts’ expectations of $25.76 million. Research analysts predict that Alimera Sciences will post -0.13 earnings per share for the current year.

Institutional Investors Weigh In On Alimera Sciences

Several large investors have recently added to or reduced their stakes in ALIM. Fifth Lane Capital LP bought a new position in shares of Alimera Sciences in the first quarter worth approximately $83,000. Vanguard Group Inc. increased its holdings in shares of Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after buying an additional 396,506 shares during the last quarter. Hillsdale Investment Management Inc. bought a new stake in shares of Alimera Sciences during the 1st quarter worth $169,000. Ancora Advisors LLC bought a new stake in shares of Alimera Sciences during the 1st quarter worth $915,000. Finally, Deltec Asset Management LLC purchased a new position in Alimera Sciences in the second quarter worth $690,000. Institutional investors own 99.83% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).